Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi ...

U.S. stocks closed higher on Friday, led by a tech-sector rebound, with the Dow surging more than 400 points and all three major indexes ...

<?xml encoding="utf-8" ?> A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh ...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

Learn more Moderna (MRNA) and other vaccine developers were up on Friday after The New York Times reported that the National Institutes of Health is part of a public-private partnership to accelerate ...

Novavax jumped 20% and Moderna rose 7% after a Russian lab worker died from suspected plague exposure. Vaccine and biodefense ...

Vaccine stocks including Novavax and Moderna rallied after a lab technician died following suspected plague exposure at a ...

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.

Sanofi CEO Belén Garijo described the firm’s more than two-decade partnership with Regeneron as “one of the most productive ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly ...